Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Damora Therapeutics, Inc.GLTO · Entity 4602 | Chief Operating Officer | January 05, 2026 | January 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Damora Therapeutics, Inc.
Report date January 05, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 190,376 |
Reported balance
After 2026-01-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-05 · Grant · Acquired 190,376 · Balance 190,376 F1: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one share of common stock of the Issuer. The RSUs will vest with respect to 25% on each anniversary of the grant date through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.82 · Expires 2036-01-05 | Direct | 444,209 |
Reported balance
After 2026-01-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-05 · Grant · Acquired 444,209 · Balance 444,209 F2: This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on January 5, 2027 and in equal monthly installments thereafter through January 5, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one share of common stock of the Issuer. The RSUs will vest with respect to 25% on each anniversary of the grant date through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F2: This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on January 5, 2027 and in equal monthly installments thereafter through January 5, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2026 Filed Jan 27, 2026 02:04 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantStock Option (right to buy) · Derivative | 444,209 | $0.00 Strike: $21.82 | $0.00 |
DisclosureSEC source: 0001193125-26-023094 · ownership.xml · derivative · entry 2 Sattarzadeh Sherwin · CIK 0002107268 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,209 Underlying: Common Stock · 444,209 shares Expires 2036-01-05 F2 · derivative.exercise_date: This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on January 5, 2027 and in equal monthly installments thereafter through January 5, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
| January 05, 2026 Filed Jan 27, 2026 02:04 UTC | Damora Therapeutics, Inc. GLTO · Entity 4602 | GrantCommon Stock | 190,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-023094 · ownership.xml · nonDerivative · entry 1 Sattarzadeh Sherwin · CIK 0002107268 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,376 F1 · security: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one share of common stock of the Issuer. The RSUs will vest with respect to 25% on each anniversary of the grant date through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.